Explainer8 min read
Semax nasal spray: what the intranasal studies show
Semax was developed in Russia as nasal drops. What the intranasal stroke and imaging studies measured, how nasal and injected data compare, and what the July 2026 PCAC meeting means.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
The short answer: semax nasal spray is the form semax was designed for. The drug was developed in Moscow as intranasal drops, and every human study of semax we could find in PubMed used the nose. [3] Those studies are small, open label, published in Russian, and run by the group that created the drug, so they suggest effects in stroke and optic nerve disease without proving them. [4] In the United States, semax is not an approved drug and is not on the 503A bulks list, and FDA's own briefing for the July 2026 advisory committee recommended against listing it. [16] A draft HHS policy released October 28, 2026 says HHS does not intend to take enforcement action against licensed compounding of single-ingredient semax for intranasal use only, under strict conditions; it is not an approval. [1]
This explainer covers what the intranasal research measured and what the legal picture means. It does not give dosing or administration instructions. For the full evidence record, see the semax entity page.
What is semax nasal spray?
Semax is a seven amino acid fragment of the stress hormone ACTH with a Pro-Gly-Pro tail added for stability. Its developers describe it as one of the rare regulatory peptides that went from basic research into clinical use in Russia, where it is given intranasally. [3] The research-use sprays sold online borrow that route, but they are not the Russian registered product and are not approved in the United States in any form. Searches for "semax spray", "nasal semax" and "intranasal semax" all point at the same thing: the peptide delivered through the nose.
Why is semax given as nasal drops?
Two findings from the developing institute explain the choice of route.
First, semax reaches the brain quickly through the nose. In rats given radiolabeled semax intranasally, about 0.093% of the dose per gram of tissue was found in the brain two minutes later, and 80% of that radioactivity was still intact semax. [7]
Second, semax breaks down fast once it is in the body. The same rat study found rapid enzymatic degradation, with the Pro-Gly-Pro fragment dominating in blood and tissue samples. [7] A later study tested how semax and shorter glyprolines held up against enzymes from nasal mucus, brain membranes and rat blood, and found semax was cleaved to a shorter His-Phe-Pro-Gly-Pro fragment. [10]
Put together, the rationale is a short path to the brain for a peptide that does not survive long in circulation. That is a pharmacology argument from rodents. It has not been confirmed with human brain measurements.
What did the intranasal semax trials measure?
Every human efficacy study we found used intranasal semax on top of standard care, compared with standard care alone.
- Acute ischemic stroke (1997). Patients in the acute period of hemispheric stroke who received intranasal semax with standard therapy showed faster regression of neurological deficit and better EEG measures than patients on standard therapy alone. The study was open, not blinded, and had no placebo. [4]
- Chronic cerebrovascular insufficiency (2005). Courses of semax were associated with fewer exacerbations and slower progression over follow-up, again in an open comparison. [6]
- Stroke across stages (2018). The same research group reported better functional recovery when semax was added at different stages of ischemic stroke. [11]
- Optic nerve disease (2000). Patients with several types of optic nerve disease received semax as nasal drops or by endonasal electrophoresis alongside standard treatment, and the authors reported better visual acuity, visual fields and nerve conduction than controls. [5]
There is also one imaging study in healthy adults. Twenty-four volunteers had resting-state brain scans before and 5 and 20 minutes after intranasal semax (14 people) or placebo (10 people), and the semax group showed changes in the default mode network. [12] A change on a brain scan is not a change in memory, focus or mood, and this study did not measure those outcomes.
What is missing matters more than what is there. There is no double-blind, placebo-controlled semax trial described in an indexed English-language report, no independent replication outside the developing network, and no controlled study of semax as a nootropic in healthy people. That is why our semax evidence grade is human observational rather than randomized. The stroke recovery page and the cognitive decline page set these findings beside treatments with stronger evidence. Our guide to reading a peptide study explains why open-label, single-group research carries so much less weight.
Semax nasal spray vs injections: what does the data show?
Searches for "semax injections" usually come from products sold as injectable powders. The comparison rests on animal work alone.
In a rat study that gave semax by both routes, intranasal semax improved learning in a passive avoidance task at lower doses than intraperitoneal injection. Injection, however, reduced pain sensitivity, and the nasal route did not. The authors concluded that the two effects probably run through different brain structures. [9]
The rodent mechanism work that underpins the cognitive claims also used the nose: a single intranasal dose raised hippocampal BDNF protein and its trkB receptor within hours. [8] No human study has compared nasal and injected semax, and injected semax has no published human data at all.
Is semax nasal spray legal? What the PCAC meeting means
Semax has moved through four regulatory stages in three years.
- Category 2. FDA placed semax on its 503A Category 2 list of bulk substances that may present significant safety risks in 2023, and in April 2026 moved it to a list of nominations withdrawn by their nominators. A withdrawn substance is in no 503A category, so FDA's own Category 1 interim policy does not cover it. [14]
- Advisory meeting. FDA presented semax to the Pharmacy Compounding Advisory Committee on July 23 to 24, 2026. [16] FDA's drug center recommended against listing it, and the advisory committee voted in favor. [1] The committee advises FDA; its vote does not change the law.
- No rule proposed. Semax is not on the 503A bulks list, and FDA has proposed no rule to add it. [15]
- Draft HHS policy. On October 28, 2026, HHS released a draft enforcement discretion policy saying it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds single-ingredient semax for intranasal use only, on a patient-specific prescription, when all of the policy's conditions are met. [1] That is not an FDA approval or a 503A bulks listing, it is not binding, and HHS may revisit it; the notice was published in the Federal Register on October 30, 2026. [2] Injected semax, blends, and modified versions such as N-acetyl semax amidate are not covered, and state law still applies.
Semax is not an FDA approved drug, and research-labeled sprays are not lawful for human use. The semax regulatory tracker logs each dated step, the PCAC vote explainer covers the meeting, and the legal hub covers state rules. Our explainer on the draft HHS policy covers its conditions and what did not change. For how prescribing works once a substance is listed, see how to get peptides prescribed. Our explainer on what peptide therapy is covers how clinics use the term.
Advertised prices for research-labeled semax are not a comparable figure, because those products are not lawful for human use. The semax cost page explains why advertised prices are not a benchmark.
Semax nasal spray side effects and safety
No blinded safety trial exists. The developers wrote in 1997 that semax produced no negative side effects or complications in their clinical experience. [3] That is a claim from the team that created the drug, based on uncontrolled use, not a systematic safety review. Our entity record lists nasal irritation as the most common complaint and anecdotal reports of anxiety, irritability or poor sleep, none confirmed by a controlled study.
Product quality is a separate risk. When a Belgian medicines laboratory analyzed two seized preparations in 2017 and 2018, it found semax and selank, noted that these peptides had not completed clinical trials, and found them freely sold online as injectable powders and nasal sprays. [13] A research-labeled spray has no verified identity, purity, sterility or strength.
For athletes, semax is not named on the WADA Prohibited List, and its status under the non-approved substances section is unclear because it is registered in Russia. [17]
Semax nasal spray vs selank nasal spray
Semax and selank are often sold side by side as sprays, and many people search for them together. They are different molecules with different evidence: semax was studied mainly in stroke, selank mainly in anxiety. FDA presented semax to the advisory committee in July 2026, and selank was not among the peptides FDA presented. Semax is one of six peptides named in HHS's October 2026 draft enforcement discretion policy; selank is not. [1] The semax vs selank comparison owns the head-to-head. The selank nasal spray explainer covers the combination question, and our post on N-acetyl semax and selank amidate covers the modified versions sold online.
The bottom line
Semax nasal spray is the route with the most research behind it, but that research is a handful of open-label Russian studies and rodent pharmacology. It has no controlled trial in healthy adults and no approval in the United States. FDA's own briefing for the July 2026 meeting recommended against listing semax, and FDA has proposed no rule. HHS's October 2026 draft enforcement discretion policy covers single-ingredient intranasal semax only, under strict conditions, and is not an approval. We will update this page as the policy and any FDA rule move forward.
What's actually offered, and what that means for you
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [18] [19] [20]
What that means for you
- A pharmacy that compounds semax relies on HHS's draft policy, which has strict conditions and which HHS can revisit, so it carries some regulatory risk. Compounding it outside those conditions, such as in a blend or by another route, has no federal basis. [1]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [21]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [22]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [23] [24]
If you're going ahead anyway
Each step is on the semax page: check the pharmacy's license, what a legitimate prescription and consult look like, why this is safer than a research-use-only product, and questions to ask. These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [21]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
Pages referenced in this article
- PeptideSemax
- RegulatorySemax regulatory timeline
- ComparisonSemax vs Selank
- CostSemax cost
- ConditionStroke recovery
- ConditionCognitive decline and nootropic use
- IndexState legal guides
Frequently asked questions
Does semax nasal spray work?
The human evidence is thin. Russian open-label studies report faster recovery after ischemic stroke and fewer exacerbations of chronic cerebrovascular disease when intranasal semax was added to standard care, but none was blinded or placebo controlled, and none has been independently replicated. There is no controlled trial in healthy adults using it as a nootropic. [4] [6] [11]
Is semax nasal spray better than semax injections?
No human study has compared the two. In rats, intranasal semax reached the brain within minutes and improved learning at lower doses than intraperitoneal injection, but it did not reproduce the pain-relief effect seen with injection. Injected semax sold online has no published human data. [7] [9]
Is semax nasal spray legal in the US?
It is not an FDA approved drug and is not on the 503A bulks list. FDA moved semax from its 503A Category 2 list to its list of withdrawn nominations in April 2026. At the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA's drug center recommended against listing it, and the committee voted in favor. Under a draft HHS policy released October 28, 2026, HHS says it does not intend to take enforcement action against licensed compounding of single-ingredient semax for intranasal use only, on a patient-specific prescription, when all of the policy's conditions are met. That is not an FDA approval, and HHS may revisit it. Research-labeled sprays are still not lawful for human use. [1] [14] [15] [16]
What are the side effects of semax nasal spray?
No blinded safety trial exists. The developers reported no complications in their clinical experience, but those are uncontrolled reports from the group that created the drug. Products sold online as semax sprays are unapproved and not verified for identity or purity. [3] [13]
Is semax banned in sport?
Semax is not named on the WADA Prohibited List. Because it is registered in Russia it may not fall under the section for non-approved substances, so its status is unclear and athletes should check with their anti-doping organization. [17]
Sources
Numbered citations in the article point to these primary sources. PubMed entries link to the indexed abstract. Evidence grades follow our methodology.
- [1]HHS: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendix A and Appendix B (draft, October 2026)2026
- [2]Federal Register: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; Notice of availability (HHS Office of the Secretary, FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496, published October 30, 2026)Federal Register, 2026
- [3]Ashmarin IP et al. A nootropic adrenocorticotropin analog 4-10, semax (15 years experience in its design and study). Zh Vyssh Nerv Deiat Im I P Pavlova 1997PubMed 9173745, 1997
- [4]Gusev EI et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova 1997PubMed 11517472, 1997
- [5]Polunin GS et al. Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Vestn Oftalmol 2000PubMed 10741256, 2000
- [6]Gusev EI et al. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova 2005PubMed 15792140, 2005
- [7]Shevchenko KV et al. Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorg Khim 2006PubMed 16523722, 2006
- [8]Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res 2006PubMed 16996037, 2006
- [9]Manchenko DM et al. Nootropic and analgesic effects of Semax following different routes of administration. Ross Fiziol Zh Im I M Sechenova 2010PubMed 21268834, 2010
- [10]Shevchenko KV et al. Proteolysis of simple glyprolines by leucine aminopeptidase and enzymes from nasal slime, brain membranes, and rat blood. Bioorg Khim 2013PubMed 24397030, 2013